Obesity

Longitudinal Analysis of Obesity Drug Use and Public Awareness

JAMA Netw OpenPublished Repeated cross-sectional study

Authors' conclusion

This repeated cross-sectional study shows the dynamic growth and evolving share of new obesity medications since 2017 and a significant shift toward semaglutide and tirzepatide prescribing. The joint surge in prescriptions and online searches and their close correlation highlight the real-time associations between public awareness and prescription trends.

Study context

Population
US retail prescriptions for FDA-approved obesity management drugs (IQVIA National Prescription Audit, ≈90% of US retail dispensing) and Google searches, July 1, 2017 to February 29, 2024
Outcome
Trends in OMD prescriptions and online searches; correlation by Spearman rank correlation
Methodological detailspopulation-level
  • Population-level

Main finding

As reported in the abstract

July 2017 to February 2024
OMD prescriptions dispensed in the US during study period
69 213 936
Mean (SD) annual growth rate
5.3% (9.4%)
Total monthly OMD prescriptions, February 2024
1.5 million
Share of all prescriptions, February 2024
0.41%
Monthly prescriptions Feb 2024: phentermine / Wegovy / Zepbound
0.74 million / 0.42 million / 0.25 million
Searches per 10 million, Feb 2024: Wegovy / Zepbound / phentermine
636.3 / 468.9 / 301.8
Prescription–search correlation, semaglutide (Wegovy)
r = 0.97
Prescription–search correlation, tirzepatide (Zepbound)
r = 0.90

Observational data: associations, not effects.

Further findings

Prescriber share of OMD prescriptions · July 2017 to February 2024

Advanced practice practitioners (APP) share
25.3% to 40.6%
PCP and internist share
57.9% to 48.1%

Drug share of total obesity management drugs (OMDs) among APPs and primary care physicians (PCPs)/internists, respectively · February 2024 (phentermine from July 2017)

Wegovy share
27.7% and 28.3%
Zepbound share
16.1% and 16.5%
Phentermine share, July 2017 to February 2024
86.3% and 85.1% to 50.8% and 49.7%

Original publication

Longitudinal Analysis of Obesity Drug Use and Public Awareness. JAMA Netw Open. Published 2 January 2025. doi:10.1001/jamanetworkopen.2024.57232

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.